BBI 3000

Drug Profile

BBI 3000

Alternative Names: BBI-3000

Latest Information Update: 27 Jan 2016

Price : $50

At a glance

  • Originator Undisclosed
  • Class Retinoids; Small molecules
  • Mechanism of Action Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acne

Most Recent Events

  • 27 Jan 2016 Preclinical development is ongoing in USA
  • 30 Jun 2014 BB 3000 licensed to Merz North America in North America
  • 04 Mar 2013 Preclinical trials in Acne in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top